查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371880

到 2030 年心臟病學人工智慧市場預測：按組件、用途、最終用戶和地區進行的全球分析

Artificial Intelligence In Cardiology Market Forecasts to 2030 - Global Analysis By Component (Software, Hardware and Services), Application (Stroke, Cardiac Arrhythmias, Ischemic Heart Disease and Other Applications), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

據Stratistics MRC稱，2023年全球心臟病學人工智慧市場規模為7.4408億美元，預計到2030年將達到7.4661億美元，預測期內年複合成長率為36.1%，預計還會成長。

心臟病學中的人工智慧（AI）是指應用機器學習演算法和計算模型來分析心臟相關的醫療資料。這項技術顯示出改變心臟病診斷、監測和治療方式的巨大潛力。人工智慧演算法可以幫助解釋超音波心動圖並進行自動檢測並識別異常情況。人工智慧模型可以根據年齡、病歷和生活方式等要素評估患者心血管疾病的風險。人工智慧驅動的系統可以透過穿戴式裝置持續監測心臟病患者，並就任何令人擔憂的變化向醫療保健提供者提供即時警報。

根據美國國家生物技術資訊中心（NCBI）2022年發布的一項最新研究，人工智慧演算法對心律不整進行分類的準確率高達95.4%。此外，AI對此疾病進行分類的特異性為94.52%，陽性預測值為89.74%，陰性預測值為98.55%，敏感度為97.19%。這項研究的研究人員得出的結論是，人工智慧的使用將誤報率降低了 98.0%。

心血管疾病增加

全世界心血管疾病的患病正在增加。因此，對人工智慧等輔助診斷和治療的尖端工具的需求不斷成長。人工智慧驅動的診斷技術可以更早發現心律不整，實現及時治療，並可能阻止疾病的未來發展。心血管疾病患者可能會受益於人工智慧帶來的更準確的診斷和治療策略。由於循環系統疾病發生率的增加，法規對循環系統技術和進步的興趣增加。這可以創造一個有利於人工智慧解決方案的創建和使用的環境。

複雜的監管核准和認證

獲得人工智慧醫療設備和應用程式的法規核准可能是一個漫長而複雜的過程。公司必須向法規證明其人工智慧解決方案的安全性、有效性和臨床有效性。人工智慧應用必須遵守醫療實踐中的道德準則。此外，確保人工智慧演算法公平且不存在基於種族、性別或其他人口要素的偏見也是一個關鍵的法規問題。

擴大電子健康記錄(EHR) 的採用

透過電子健康記錄(EHR) 可以獲得各種有組織和非結構化的患者資料，例如病歷、診斷測試、治療計劃和處方箋。人工智慧演算法可以利用 EHR 來分析比手動分析更多的患者群體的資料。因此，有可能獲得心臟問題更強大、更具統計意義的見解，從而得出更準確的診斷和治療方法提案。人工智慧還可以幫助減少電子病歷資料輸入錯誤並提高病患記錄的準確性和完整性。因此，EHR 和人工智慧在循環系統的整合將推動市場成長。

有限的概括

如果人工智慧系統無法有效泛化，它們可能無法識別重要的心臟疾病或標記誤報/陰性，這可能導致錯誤的醫療決策。它可能會給患者帶來不良後果，並產生法律和道德影響。如果醫療保健專業人員始終提供不準確或不可靠的結果，他們可能會失去對人工智慧系統的信任。這可能會阻礙其在臨床實踐中的採用和接受。

COVID-19 的影響

COVID-19大流行對人工智慧在醫療保健和心臟病學領域的採用產生了直接和間接的影響。鎖門和社交距離措施導致對遠端醫療和遠端監控解決方案的需求激增。包括循環系統在內的人工智慧工具在促進虛擬諮詢和遠端監測患者心臟狀況方面發揮了關鍵作用。 AI 演算法很快就被部署來幫助診斷和分類 COVID-19 病例。盡量減少面對面互動的需求導致人們更加關注遠端影像，而人工智慧在解釋影像和協助診斷心臟病方面發揮關鍵作用。

預計軟體領域在預測期內將是最大的產業

由於對人工智慧驅動的診斷解決方案的需求不斷增加，軟體領域預計將出現良好的成長。透過資料分析，基於人工智慧的軟體可以改善醫療決策。心電圖在人工智慧演算法的輔助下，可以減少患者診斷時間並識別異常情況。此外，該軟體還提高了工作效率並提供更好的心臟分析。這些要素正在推動心臟病學領域對人工智慧軟體的需求。

心律不整領域預計在預測期內年複合成長率最高

心律不整領域預計在預測期內年複合成長率最高。 AI演算法可以分析心電圖（ECG）來識別和分類不同類型的心律不整，包括心房顫動、心室心搏過速和心搏過緩。人工智慧演算法可以處理動態心電圖監測儀收集的長期心電圖資料。可以識別並記錄心律不整發作，以供醫療保健提供者稍後查看。此外，個體化治療計劃、遠端醫療和心電圖解讀協助正在推動這一領域的成長。

比最大的地區

由於醫療基礎設施完善、技術先進產品的快速採用以及人工智慧產品法規的核准增加，預計北美將在預測期內佔據最大的市場佔有率。北美，特別美國，是創新和發展的中心。該地區還吸引了大量醫療保健技術投資，包括人工智慧應用。此外，對遠端醫療的日益重視以及對以患者為中心的護理日益濃厚的興趣也推動了市場需求。

複合年複合成長率最高的地區：

由於老年人口的增加、醫療基礎設施的發展和經濟狀況的改善，預計亞太地區在預測期內將出現最高的年複合成長率。此外，該地區心血管疾病的患病很高。中國的CVD病例數位居第一。因此，該地區的高疾病負擔和不發達的醫療基礎設施有望提高人工智慧在心臟診斷和治療中的應用。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球人工智慧在心臟病學市場的應用：按組成部分

  • 軟體
  • 硬體
  • 服務

第6章 全球人工智慧在心臟病學市場的應用：按應用分類

  • 中風
  • 心律不整
  • 缺血性心臟疾病
  • 其他用途

第7章 全球人工智慧在循環系統市場的應用：依最終用戶分類

  • 醫療保健付款人
  • 生命科學公司
  • 醫療服務提供方

第8章 全球心臟病學市場人工智慧：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Arterys Inc.
  • IDOVEN
  • Cardiologs
  • Ultrasight
  • Ultromics Limited
  • DiA Imaging Analysis
  • CardiAI
  • Viz AI
  • Cleerly, Inc
  • RSIP Vision
  • Vista AI
  • HeartVista Inc
  • Caption Health
  • HeartFlow
  • Bay Labs
  • Siemens Healthineers
  • NuvoAir
  • PathAI
Product Code: SMRC23936

According to Stratistics MRC, the Global Artificial Intelligence in Cardiology Market is accounted for $744.08 million in 2023 and is expected to reach $746.61 million by 2030 growing at a CAGR of 36.1% during the forecast period. Artificial Intelligence (AI) in cardiology refers to the application of machine learning algorithms and computational models to analyze medical data related to the heart. This technology has shown tremendous promise in transforming the way cardiac conditions are diagnosed, monitored, and treated. AI algorithms can assist in the interpretation of echocardiograms, providing automated measurements and identifying abnormalities. AI models can assess a patient's risk of developing cardiovascular diseases based on factors like age, medical history, and lifestyle. AI-powered systems can continuously monitor patients with heart conditions through wearable devices, providing real-time alerts to healthcare providers for any concerning changes.

According to a recent study published by the National Center for Biotechnology Information (NCBI) in 2022, an AI algorithm classified arrhythmia with 95.4% accuracy. Furthermore, AI classified the disease with a specificity of 94.52%, positive predictive value of 89.74%, negative predictive value of 98.55%, and 97.19% sensitivity. The researchers of the study concluded that AI's use would reduce the overall false-positive results by 98.0%.

Market Dynamics:

Driver:

Rising cardiovascular disease rates

The prevalence of cardiovascular ailments is rising on a global scale. As a result, there is an increasing demand for cutting-edge tools like AI to aid in diagnosis and treatment. AI-powered diagnostic technologies can spot cardiac irregularities sooner, enabling prompt treatment and perhaps halting the disease's future progression. Cardiovascular disease patients may benefit from more precise diagnosis and treatment strategies made possible by AI. Increased regulatory attention to cardiology-related technologies and advances may result from the growing frequency of cardiovascular disorders. This may foster an environment that encourages the creation and use of AI solutions.

Restraint:

Complex regulatory approval and certification

Obtaining regulatory approval for AI-based medical devices or applications can be a lengthy and complex process. Companies must demonstrate the safety, efficacy, and clinical validity of their AI solutions to regulatory bodies. AI applications must adhere to ethical guidelines in medical practice. Further, ensuring that AI algorithms are fair and do not introduce biases based on race, gender, or other demographic factors acts as a significant regulatory concern.

Opportunity:

Increasing adoption of Electronic Health Records (EHRs)

A variety of organised and unstructured patient data, including as medical histories, diagnostic tests, treatment plans, prescriptions, and more, is available through electronic health records (EHRs). AI algorithms can analyse data from a far wider patient population using EHRs than they could manually. This makes it possible to get stronger and statistically significant insights into heart problems, which may result in more precise diagnosis and therapy suggestions. AI may also aid in reducing data input mistakes in EHRs and enhancing the precision and thoroughness of patient records. Therefore, the integration of AI with EHRs in cardiology fuels the growth of the market.

Threat:

Limited generalization

If the AI system is not able to generalize effectively, it may fail to identify important cardiac conditions or may flag false positives/negatives, potentially leading to incorrect medical decisions. It leads to adverse patient outcomes and there could be legal and ethical implications. Healthcare professionals may lose confidence in the AI system if it consistently provides inaccurate or unreliable results. This can hinder its adoption and acceptance in clinical practice.

COVID-19 Impact

The COVID-19 pandemic has had both direct and indirect impacts on healthcare and the adoption of AI in cardiology. Due to lockdowns and social distancing measures, there was a surge in demand for telemedicine and remote monitoring solutions. AI-powered tools, including those in cardiology, played a significant role in facilitating virtual consultations and remote monitoring of patients' cardiac conditions. AI algorithms were swiftly deployed to assist in the diagnosis and triage of COVID-19 cases. The need for minimizing in-person interactions led to an increased focus on remote diagnostic imaging, where AI can play a crucial role in interpreting images and aiding in the diagnosis of cardiac conditions.

The software segment is expected to be the largest during the forecast period

The software segment is estimated to have a lucrative growth, due to the growing need for AI-enabled diagnostic solutions. Through data analysis, AI-based software improves medical decision-making. The ECG, aided by AI algorithms, has shortened the time it takes to diagnose patients and is capable of identifying anomalies. Moreover, this software increases productivity and provides better heart analysis. These factors are improving the demand for AI software in cardiology.

The cardiac arrhythmias segment is expected to have the highest CAGR during the forecast period

The cardiac arrhythmias segment is anticipated to witness the highest CAGR growth during the forecast period. AI algorithms can analyze electrocardiograms (ECGs) to identify and classify various types of arrhythmias, including atrial fibrillation, ventricular tachycardia, and bradycardia. AI algorithms can process long-term ECG data collected by Holter monitors. They can identify and record episodes of arrhythmias for later review by healthcare providers. In addition, personalized treatment planning, telemedicine and ECG interpretation assistance are boosting the segment growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its well-established healthcare infrastructure, rapid adoption of technologically advanced products, and increased regulatory approvals of AI products. North America, particularly the United States, is a hub for technological innovation and development. Also, the region attracts significant investment in healthcare technology, including AI applications. Moreover, the growing emphasis on telemedicine and growing focus on patient-centric care is propelling the market demand.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the growing geriatric population, developing healthcare infrastructure, and improvement in the region's economic conditions. Moreover, there is a high prevalence of cardiovascular diseases in the region. China is positioned in top for CVD patient's records. Therefore, the region's high disease burden and developing healthcare infrastructure are expected to improve the adoption of AI in cardiac diagnosis and treatment.

Key players in the market:

Some of the key players profiled in the Artificial Intelligence In Cardiology Market include: Arterys Inc., IDOVEN, Cardiologs, Ultrasight, Ultromics Limited, DiA Imaging Analysis, CardiAI, Viz AI, Cleerly, Inc, RSIP Vision, Vista AI, HeartVista Inc, Caption Health, HeartFlow, Bay Labs, Siemens Healthineers, NuvoAir and PathAI.

Key Developments:

In August 2023, Siemens Healthineers unveils the Acuson Origin1, a dedicated cardiovascular ultrasound system with new, robust artificial intelligence (AI) features. Designed to improve patient outcomes and help physicians perform minimally invasive cardiac procedures more efficiently, the Acuson Origin addresses the entire continuum of cardiovascular patient care, including diagnostic, structural heart, electrophysiological, and pediatric procedures.

In February 2023, DiA Imaging Analysis received U.S. FDA clearance for its LVivo IQS software solution, which is used to provide high-quality echocardiography images of the heart to physicians.

In April 2022, Arterys has launched Strain + AI a new cardio AI feature. Strain + AI has beautiful, easy to interpret color and vector overlays, 17-segment models, and plot curves and automatically provides strain and strain rate decomposed into radial and circumferential components as well as myocardial velocity.

Components Covered:

  • Software
  • Hardware
  • Services

Applications Covered:

  • Stroke
  • Cardiac Arrhythmias
  • Ischemic Heart Disease
  • Other Applications

End Users Covered:

  • Healthcare Payers
  • Life Science Companies
  • Healthcare Providers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Artificial Intelligence In Cardiology Market, By Component

  • 5.1 Introduction
  • 5.2 Software
  • 5.3 Hardware
  • 5.4 Services

6 Global Artificial Intelligence In Cardiology Market, By Application

  • 6.1 Introduction
  • 6.2 Stroke
  • 6.3 Cardiac Arrhythmias
  • 6.4 Ischemic Heart Disease
  • 6.5 Other Applications

7 Global Artificial Intelligence In Cardiology Market, By End User

  • 7.1 Introduction
  • 7.2 Healthcare Payers
  • 7.3 Life Science Companies
  • 7.4 Healthcare Providers

8 Global Artificial Intelligence In Cardiology Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Arterys Inc.
  • 10.2 IDOVEN
  • 10.3 Cardiologs
  • 10.4 Ultrasight
  • 10.5 Ultromics Limited
  • 10.6 DiA Imaging Analysis
  • 10.7 CardiAI
  • 10.8 Viz AI
  • 10.9 Cleerly, Inc
  • 10.10 RSIP Vision
  • 10.11 Vista AI
  • 10.12 HeartVista Inc
  • 10.13 Caption Health
  • 10.14 HeartFlow
  • 10.15 Bay Labs
  • 10.16 Siemens Healthineers
  • 10.17 NuvoAir
  • 10.18 PathAI

List of Tables

  • Table 1 Global Artificial Intelligence In Cardiology Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
  • Table 3 Global Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
  • Table 4 Global Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
  • Table 5 Global Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
  • Table 6 Global Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
  • Table 7 Global Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
  • Table 8 Global Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
  • Table 9 Global Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
  • Table 10 Global Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 11 Global Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
  • Table 12 Global Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
  • Table 13 Global Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
  • Table 14 Global Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
  • Table 15 North America Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
  • Table 17 North America Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
  • Table 18 North America Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
  • Table 19 North America Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
  • Table 20 North America Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
  • Table 21 North America Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
  • Table 22 North America Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
  • Table 23 North America Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
  • Table 24 North America Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 North America Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 North America Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
  • Table 27 North America Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
  • Table 28 North America Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
  • Table 29 Europe Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
  • Table 31 Europe Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
  • Table 32 Europe Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
  • Table 33 Europe Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
  • Table 34 Europe Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
  • Table 35 Europe Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
  • Table 36 Europe Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
  • Table 37 Europe Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
  • Table 38 Europe Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 39 Europe Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
  • Table 40 Europe Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
  • Table 41 Europe Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
  • Table 42 Europe Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
  • Table 43 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
  • Table 45 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
  • Table 46 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
  • Table 47 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
  • Table 48 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
  • Table 49 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
  • Table 50 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
  • Table 51 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
  • Table 52 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 53 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
  • Table 54 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
  • Table 55 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
  • Table 56 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
  • Table 57 South America Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
  • Table 59 South America Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
  • Table 60 South America Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
  • Table 61 South America Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
  • Table 62 South America Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
  • Table 63 South America Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
  • Table 64 South America Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
  • Table 65 South America Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
  • Table 66 South America Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 67 South America Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
  • Table 68 South America Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
  • Table 69 South America Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
  • Table 70 South America Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
  • Table 71 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
  • Table 73 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
  • Table 74 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
  • Table 75 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
  • Table 76 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
  • Table 77 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
  • Table 78 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
  • Table 79 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
  • Table 80 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 81 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
  • Table 82 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
  • Table 83 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
  • Table 84 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)